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Introduction 
This is the sixth of a series of cases provided and discussed by UK clinical ethics committees. This 
series developed from the Virtual Ethics Committee, which discussed a case in each issue of the 
first two volumes of the journal. We invited all clinical ethics committees registered with the UK 
Clinical Ethics Network to volunteer to submit and then discuss a case, with cases allocated 
according to the experience of the committee. Committees have not discussed their own cases. 
The committees were given some guidance on how to generate a case, including the advice that 
unless consent from all parties to a case could be obtained, we would prefer fictional cases. The 
editorial committee took this decision to safeguard patient confidentiality. To the same end, we 
decided that the committee referring a case would not be identified (as this would provide a 
geographical indicator of identity), but we would name the committee discussing the case. A 
member of the editorial committee attends the discussion of the case and writes the summary to 
be published in Clinical Ethics, once the discussing committee and the journal editors have 
approved it. All committees and all of our readers individually, are invited to respond to the 
summary of the discussion once printed.  Following the journal’s usual review process, we 
welcome short articles or letters expanding upon points raised by the discussing committee or 
sharing similar experiences. We are also interested in publishing examples of good practice or 
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guidelines on difficult areas that have been generated by clinical ethics committees during the 
course of their work.  
We have had a terrific response to the invitation to participate in this series from clinical ethics 
committees based all over the UK, and have seen some lively case discussion. Future report series 
(starting with volume 5) will examine the contributions of Clinical Ethics Committees to 
organisational policy-making. Committees which would like to participate should contact the Case 
Studies editor: Ainsley Newson (ainsley.newson@bristol.ac.uk). 
 
The St George’s Clinical Ethics Committee (CEC) agreed to discuss the case presented here. The 
Committee was established in 2006 and grew out of its predecessor, the Clinical Ethics Forum, 
established in 2000. The Committee provides a service for St. George’s Healthcare NHS Trust, St. 
George’s, University of London and South West London and St. George’s Mental Health NHS Trust.  
 
The CEC was established with a comprehensive remit in relation to clinical ethics. Its mode of 
operation is both reactive and proactive, including developing links with the framework of clinical 
governance. The Chair of the CEC sits on the Trust’s Patient Safety Committee; however to 
maintain trust and neutrality, the CEC does not formally report to clinical governance committees. 
 
The CEC comprises over twenty five members, drawn from a wide range of professions, specialties 
and services (including doctors, nurses, allied health professionals and support department 
workers), with varying levels of seniority (including two medical students). There are also lay 
members and members with formal training in medical ethics, a lawyer and a chaplain. The CEC is 
currently trying to increase the diversity of its membership to better reflect the local population. 
 
Referral to the Clinical Ethics Committee: A 30 year-old man with suspected ADHD 
 
Case description 
A 30 year-old United States citizen, Mr D, who successfully studied in the USA was referred to a 
consultant psychiatrist in the UK two years ago. He had been given a diagnosis of Attention Deficit 
Hyperactivity Disorder (ADHD) in the USA and tried various stimulants there before settling on 
Adderal (a mixed amphetamine/ methamphetamine). Upon arrival in the UK he paid for this drug 
out of his own pocket but when he could no longer afford it, he approached his general 
practitioner (GP) to ask for a prescription for it. The GP then requested a psychiatric opinion as to 
the drug’s suitability, and ongoing psychiatric supervision if it was felt the drug was clinically 
indicated.  
 
The consultant psychiatrist was not persuaded that the patient did in fact have ADHD, but agreed 
to continue the treatment whilst assessing him further to review the diagnosis. There was no way 
of obtaining third party information about Mr D from his childhood or from his treating 
psychiatrist in the USA. He concluded that the patient had difficulties in his personality and with 
forming close relationships and that the diagnosis of ADHD was obscuring the main problem. Mr D 
would not accept the suggested revised diagnosis of personality disorder nor would he 
contemplate any alternative treatment.  
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He passed examinations for Microsoft during the next year, but remained isolated, doing maths at 
home and corresponding with friends in the USA. Eventually he got a job in information 
technology, which he had held for a month. At around the same time, the GP declined to prescribe 
the drug any further, questioning the psychiatric indication, and saying it was expensive, and had 
to be ordered from the USA. The patient went for two weeks without the drug and felt his mind 
was wandering, that he was distractible, that he tended to waste time, and was worried about 
losing his job.  
 
His medication was then recommenced. However a second opinion was sought from another 
psychiatrist who concluded that, although the diagnosis could not be reliably established, it could 
not be discounted. His apparent benefit from medication argued for its potential continuation. A 
further opinion was recommended from a substance misuse specialist. This consultation 
confirmed that Mr D evidenced no signs of dependence or misuse of the stimulants, that he 
understood the potential long-term consequences of stimulant use and was competent to make 
that treatment decision.  
 
Mr D was able to continue work and, in fact, subsequently secured a better-paid job. Although he 
claimed to have good relations with work colleagues, he has not formed anything like a trusting 
friendship and remains fairly isolated. 
 
Dilemma prompting referral to the Clinical Ethics Committee 
Our team has approached the CEC to discuss the case with the following dilemma in mind: 
The key difficulty is that the psychiatrist does not feel he has a clear diagnosis which would 
justify the prescription and is authorising a prescription based purely on the balance of 
benefit and harm as perceived by the patient. Aside from the cost-benefit calculation, the 
question is: who should decide what constitutes the patient’s best interests? 
 
Response from St George’s Clinical Ethics Committee 
Thank you for your referral, which we considered at our meeting on 4th December 2008.  This case 
represented a departure from our standard process, in that it is usual for referring health 
professionals to attend our committee meetings for interactive discussion. However, this case still 
prompted a great deal of discussion and debate. The aspects of this case that we considered to be 
particularly relevant were: 
 The uncertainty over Mr D’s diagnosis; 
 The fact that he has received NHS funding for Adderal treatment in the United Kingdom; 
 Mr D’s apparent unwillingness to engage in dialogue about alternative diagnoses or 
treatments; 
 The benefits and risks of taking Adderal to Mr D; 
 The assessment of Mr D as not being prone to addiction to this drug and that he appears 
competent to weigh up the risks and benefits of taking it. 
 
The lack of diagnostic certainty 
We began by discussing the lack of certainty over Mr D’s diagnosis. There have been three 
different clinical opinions on Mr D’s diagnosis, with no confirmation of any particular condition. He 
may have Attention Deficit Hyperactivity Disorder (ADHD), Personality Disorder, both disorders, or 
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neither disorder.  Clearly additional clinical information is needed to formulate a more definitive 
diagnosis.   
 
ADHD can be difficult to diagnose, although recognition and diagnosis of this condition is 
increasing. There are a variety of problems, including inattention, impulsivity and hyperactivity; 
and two of these issues are generally required to present across two functional domains (such as 
home, school or socially) before a person is 7 years old. The condition can, however, persist 
through adulthood.  There is also some relationship between childhood ADHD and adult 
Personality Disorder: children with undiagnosed ADHD often experience disapproving interactions 
with peers and adults that can impact on their personality development. 
 
The drug Adderal, a mix of methamphetamines and amphetamines, is not generally available in 
the UK. It has not been validated for treatment by the National Institute for Health and Clinical 
Excellence (NICE). Ritalin, in contrast, is comprised of methamphetamine only. Drugs of this kind, if 
administered to a person without ADHD, would cause a person to become much more alert, but in 
a person with ADHD paradoxically the opposite effect is observed. Other treatments, such as other 
tri-cyclic drugs and cognitive behavioural therapy are available and we would be interested to 
know the length to which these have been discussed with Mr D or the extent to which his GP has 
tried to elicit this information. 
 
One indicator that may suggest that Mr D has ADHD instead of personality disorder is that he does 
seem to experience an improvement in his functioning or mood when taking Adderal; if he 
suffered from Personality Disorder this would be less marked. However, if personality disordered 
he may also experience an increase in some associated behaviours, such as dishonest acts to 
obtain funds to buy more supplies of the drug, which we have no evidence of.  
 
The advantage of Adderal is that it is a slower-acting drug so it does not have to be taken as 
frequently as a drug that is made from pure methamphetamine. However a disadvantage is that as 
they are all amphetamine derivatives, these are drugs of addiction. There are also potentially 
harmful long-term effects of taking this drug, for example an increased risk of psychosis; either 
transient or as a chronic psychosis indistinguishable from schizophrenia.  It is therefore pertinent 
to examine why Mr D is so committed to this particular therapy. Even though Mr D has been 
observed to have no signs of dependence or misuse of Adderal, this situation could change in the 
longer term. 
 
Ideally the GP should continue to seek information about Mr D’s childhood and clinical history 
prior to his emigration to the UK, as this is pivotal to attempting to resolve questions over his 
diagnosis. We also wonder why Mr D appears unwilling or unable to disclose his relevant history or 
to allow access to those in the USA who could provide relevant information. Is this behaviour 
worthy of our suspicion or is Mr D protecting himself from potentially painful information?  
 
The status quo for Mr D is therefore one of diagnostic uncertainty, with discomfort among the 
treatment team over prescribing a drug that is not licensed for use in the UK. There could be a risk 
of harm in treating a particular condition with licensed drugs if it transpires that this is the 
incorrect diagnosis. The two options are to accept Mr D’s decision (even though this is not 
necessarily what a UK doctor would prescribe) or for the treatment team to undertake further 
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investigations before adopting this patient-centred approach. It is relevant that Mr D feels better 
when taking the drug, but a tension remains between what Mr D wants and what his treatment 
team feel is best for him.  Whatever option is chosen, consistent follow-up will be required. 
 
Who should decide what constitutes Mr D’s best interests? 
The nature of an objective ‘best interests’ calculation for Mr D is problematic, as he has been 
deemed to be competent to weigh up the putative benefits and harms of taking this treatment. 
This suggests that Mr D would be the best person to determine what constitutes his own best 
interests. However, the treatment team’s obligation to respect the patient’s request is tempered 
by their obligation not to act in ways contrary to their considered professional judgement. The 
medical team should determine best interests in light of the patient’s wishes, but cannot rely 
solely on this information. 
 
Further, making this determination of best interests is by no means straightforward. Mr D likely 
has greater insight into parts of his life and the values that guide him than the treatment team, 
particularly given the lack of background information. He will also have a better idea about what 
kinds of treatments suit him given the relatively recent period of his UK treatment. But this should 
not translate into a right to demand a specific ongoing treatment, particularly one such as Adderal.  
Further, not all patients are capable of conceptualising their future, preferring instead to take a 
shorter term view. This potential problem should be explored with Mr D and if this transpires to be 
his situation, his doctor has to explain the risks and the need to take a longer-term view to find a 
good alternative treatment.  
 
Although ‘best interests’ can be broadly construed, the medical paradigm is important. It is 
arguably irresponsible to prescribe a drug to a patient that medically harms him in the longer term 
despite the fact that it makes him feel better. Mr D may be asserting that he is better-off outside 
the typical paradigm for this treatment within the NHS, but we should be mindful to balance 
improving Mr D’s overall welfare with the long-term clinical uncertainty from taking Adderal.  
 
 We also could not overlook the fact that Mr D remains isolated. This prompted us to consider 
whether he really was indeed better when he was on Adderal. With time, he may get better 
treatment to feel and function better than he does while taking this drug. Adderal may improve 
his function but this may not help Mr D to be as well as he could be. If at all possible, a more 
thorough history should be obtained, to provide further information on other treatment attempts 
and the time allocated to them. This information will help to obtain a sound and accurate 
diagnosis and to enable the treatment team to provide care to Mr D as a ‘whole person.’ This will 
also help you to determine whether there may be a better alternative to optimise Mr D’s quality of 
life.  
 
Another relevant consideration is Mr D’s background as a United States citizen who has moved to 
the United Kingdom only relatively recently. Mr D may not fully appreciate that his UK care team 
will wish to thoroughly review his condition and the long-term effects of any medications before 
prescribing, particularly given the absence of background information. The prescription from the 
USA may indeed maximise Mr D feeling good in the shorter term, but it may never have been 
meant as long term therapy. Now that he is in the UK, Mr D’s care would need to be completely 
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reviewed. Treatment with Adderal may indeed be reasonable, but without further information, it 
would be impossible for any UK doctor to make an informed judgement.  
 
You should also bear in mind that the judgement about what lies in Mr D’s best interests will in 
effect be made every time the prescription is renewed. This places a significant burden of 
responsibility on the GP. 
 
Ethical issues arising when patient-centred wishes for medication conflict with medical opinion 
One method by which the ethical issues in this case can be systematically assessed is that ‘Four 
Topics’ method.1 Contrary to principle-based theories in medical ethics, this approach starts with 
the facts of the case and then analyses the issue according to four specific categories of 
deliberation: (1) medical indications, (2) patient preferences, (3) quality of life and (4) contextual 
features. The summary of our discussion of this case using the ‘Four Topics’ is presented in Box 1. 
 
Box 1: A proposal for a ‘Four Topics’ analysis of the case of Mr D 
Medical Indications 
What is the Diagnosis & Prognosis? What 
treatment options exist? What are the medical 
goals? 
 There is reasonable professional 
disagreement over Mr D’s diagnosis  
 Options for treatment include medication 
(both licensed and unlicensed) and 
cognitive behavioural therapy (which has a 
long waiting list) 
 The treatment goals are to maintain Mr D 
at a good level of functioning.  
 The benefits of providing the drug may 
outweigh the harms, as he is not dependent 
on the drug nor does he appear to misuse 
it.  This should be revisited at a later stage. 
Patient Preferences 
Assuming competence, what does the patient 
what? What are his/her values? What is in the 
patient’s best interests? 
 Mr D is competent and well informed 
 The dissenting diagnosis could be discussed 
with him to determine why he doesn’t 
accept it 
 Mr D could be asked whether he might 
accept a compromise whereby an 
alternative treatment is tried in the short 
term, pending further assessment. He could 
be reassured that the other drug will be 
available should this not be successful 
Quality of Life 
What effect might the proposed treatments 
have on the patient’s quality of life? 
 Mr D’s quality of life is enhanced when he is 
on the medication. If he refuses the 
compromise of alternative medication his 
quality of life may be affected 
 Withdrawal of the drug in the recent past 
lowered his quality of life, increasing his 
anxiety and distractibility. 
 The longer-term harm from taking this drug 
is uncertain 
Contextual Features 
What social, economic, legal and policy 
considerations are relevant? 
 Of relevance is the fact that Mr D was 
initially diagnosed in the United States, 
which has different diagnostic criteria for 
certain mental health conditions. This may 
explain the disagreement between the 
psychiatrists, as well as influence Mr D’s 
perception of his mental health and his 
expectations for treatment in the United 
Kingdom 
                                            
1
 Jonsen AR, Siegler M, Winslade WJ. (2006) Clinical ethics: A practical approach to ethical 
decisions in medicine, 6
th
 Ed. New York: McGraw Hill. 
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 If the patient refuses to compromise, 
treatment with the current medication 
seems preferable to non-treatment in 
terms of quality of life.  
 
 There are certainly economic and resource 
allocation considerations here, but these 
should not outweigh the benefit Mr D 
obtains from taking this medication. 
   
From this analysis, a conclusion that you might like to consider is that given the reasonable 
professional disagreement over Mr D’s diagnosis, a balancing of benefits and harms suggesting 
overall benefit, and the potential impact on his quality of life, Mr D should be asked to consider a 
compromise of a trial period with an alternative treatment, but if the new treatment should fail or 
if he resolutely refuses then he should be provided with Aderral. This would be underscored by 
regular follow-up.  
 
That said, this proposal did generate much discussion among our Committee, and there was no 
consensus. Concerns were expressed about what kind of alternative treatment could be proposed, 
as this would itself be reliant on a clear diagnosis. There was also concern that this amounted to 
prescribing to make a patient feel better without reference to a clear evidence base. Many 
members of our committee felt this was an unacceptably patient-centred proposal, which does 
not account for the medical stake in determining Mr D’s best interests. Mr D should not have the 
right to ‘order’ medications.   
 
The resource allocation implications of prescribing a drug that is not available in the UK also need 
to be considered. The decision to prescribe Adderal to Mr D will affect other patients and may set 
a precedent for future prescribing in patients with a similar presentation. If you are to prescribe 
for Mr D at all, then perhaps he should be tried with an approved British drug first under the 
supervision of his UK team. The doctor-patient relationship should also be developed to allow the 
team to know Mr D as a whole person rather than simply providing him with a pharmaceutical of 
uncertain value. A more detailed risk-benefit assessment could also then take place over a period 
of time, particularly as his condition is chronic as opposed to acute. However a counter to this 
position is that Mr D has already been prescribed Adderal in the United Kingdom and has found it 
to be of benefit despite his diagnostic uncertainty. It may therefore be seen as unreasonable to 
withhold it now. Changing his treatment could also cause a rift in the doctor-patient relationship 
as well as potentially disrupting the securities in his life such as his current job. 
 
Reaching a consensus 
We have established that Mr D does require some kind of regular treatment and follow-up, but 
the nature of this then needs to be established. Our deliberations on this led us to an admittedly 
pragmatic solution. 
 
Regardless of which treatment Mr D is eventually prescribed, you should attempt to firmly 
establish his level of functioning via an ongoing dialogue with him. Diagnostic and treatment 
uncertainty should be acknowledged and the resulting period should be used to pursue this 
further, including seeking information from others in the United Kingdom and the United States. 
This will help the doctors involved in his care to move beyond mere prescribers. 
 
8 
 
While this ongoing exchange is taking place, some form of drug treatment would seem 
appropriate, despite the diagnostic uncertainty, given that Mr D has been taking medication fairly 
constantly. After discussing the merits of prescribing a drug or prescribing Adderal, we concluded 
(taking into account the risks, Mr D’s broader interests and those of the health service) that it 
would be appropriate to provide a drug that is already available and approved for use in the 
United Kingdom. This provision would be coupled with an ongoing discussion with him about 
treatment, a commitment to reduce uncertainty in his diagnosis and to build a more complete 
doctor-patient relationship. There could well be a move to revised treatment (including Adderal, 
or withdrawing drug treatment altogether) pending further investigations and clinical deliberation; 
this should be communicated to Mr D.  
 
We believe this course of action is appropriate even though it does not concede to Mr D’s 
expressed preference. Adderal may well be low risk but until you can be absolutely sure of this it is 
not justifiable to provide this drug in place of something that has been approved for use in the 
United Kingdom. If Mr D is committed to staying well, then hopefully he will want to engage in the 
process of dialogue required to help his clinical team to reach agreement with him as to what lies 
in his best interests. In time it may emerge that the unlicensed drug is the one that is the most 
suitable for Mr D; however this conclusion should not be reached too quickly. 
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